Inito, the Bengaluru-based medical technology startup, has secured $6 million in Series A funding led by Fireside Ventures, propelling the global expansion of its revolutionary Fertility Monitor. The funding will advance Inito’s analytics capabilities using artificial intelligence and support research and development for innovative tests, underscoring the company’s commitment to disrupting the women’s healthcare market.
“We want to bring a variety of tests for fertility and beyond on a single device at home, empowering people with direct access to health information and fostering a better understanding of their bodies and health conditions,” CTO Varun A Venkatesan said.
With a total funding of $15 million, Inito is aiming for a future where its products, driven by technology and consumer-centric thinking, become as ubiquitous as thermometers in households, providing personalized reproductive health analytics and addressing various health concerns through a smartphone-based platform.
“We look forward to a day where Inito will be present in every household and be as ubiquitous as a thermometer,” added Venkatesan.
Inito’s Fertility Monitor is Revolutionizing Reproductive Health
Launched globally in mid-2021, Inito’s flagship product, the Fertility Monitor, has garnered attention with over 2.5 million tests conducted, including the confirmation of 10,000 pregnancies.
It was developed by Inito’s co-founders, Aayush Rai and Varun A Venkatesan, who left their roles at MedTech giant Siemens to pursue a vision of impacting people’s lives. The monitor measures four essential fertility hormones: estrogen, LH, progesterone metabolite (PdG), and FSH.
The latest funding round will support the global expansion of the hormone test and facilitate the development of advanced analytics using AI.
“Unlike other products that leave the interpretation of hormone values to the user, our app looks at the evolution of four hormones together and determines if the fertility rating for that day is low, high or peak and if ovulation has indeed occurred in this cycle,” CEO Aayush Rai said.
Inito aims to diversify its offerings in the long term to include diagnostic tests for various health concerns through a smartphone-based platform. Fireside Ventures, leading the investment, expressed enthusiasm for the shared commitment to making a lasting impact on healthcare.
Inito’s Journey and Future Aspirations
Founded in 2015, Inito took flight after five years of rigorous research and development. The startup, part of Y Combinator’s winter 2019 batch, has previously raised funds from Y Combinator, Varsha Rao, former Nurx CEO, and a group of physicians and family offices. Looking ahead, Inito plans to optimize its app for Android users, invest in research and development for new products, and enhance its analytics capabilities.
Inito’s Fertility Monitor starter kit, priced at $149, includes the device and 15 test strips. The device, registered with the FDA as a Class I medical device, provides numerical values of fertility hormones, offering users a whole fertile window of six days.
The device can be connected to a smartphone, and Inito’s app will list the results for the user on it. A pack of refill strips is currently available for $49. Inito’s focus on accuracy and personalization differentiates it from traditional at-home ovulation tests.
Expanding Reach and Scaling Operations
With the new funding, Inito aims to scale its business operations, expanding beyond its current availability on iOS to launch an Android app. Additionally, the startup intends to invest in R&D for new products.
“While fertility hormone testing is our first product, this funding raise will allow us to invest in R&D for new tests that cater to solving problems faced by patients and practitioners,” Rai said. Inito’s goal is to leverage its extensive dataset, derived from over 2.5 million tests, to train algorithms that correlate symptoms, moods, sleep patterns, and medications with hormonal fluctuations.
“We are building point-of-care tests for tracking pregnancy health, ovarian reserve and male fertility hormones. Our technology uses a combination of hardware, biotechnology and machine learning to improve test strips’ accuracy, reliability and density, allowing them to measure multiple parameters on a single testing platform.”
This recent Series A funding brings Inito’s total funding to $15 million. The startup’s long-term vision emphasizes providing universal access to healthcare and empowering individuals with data about their bodies. The intersection of technology and consumer-centric thinking positions Inito as a disruptor in the field, and the recent funding will propel the company’s vision forward.
- Clinikally Secures $2.6 Million Funding to Transform Dermatology Telehealth
- Doceree Secures $35 Million in Series B Funding for Global Expansion
- Pilgrim Secures $20 Million in Series B Funding Led by Vertex Ventures
- Oorja Bags $1.5 Million in Funding to Promote Clean Mobility with Innovative Tech
- Zolve Secures $100 Million Loan from CIM to Strengthen Immigrant Banking in the US